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Abstract Preclinical vascular research has been hindered
by a lack of methods that can sensitively image and quantify
vascular perfusion and leakage in vivo. In this study, we have
developed dynamic near-infrared imaging methods to
repeatedly visualize and quantify vascular leakage in mouse
skin in vivo, and we have applied these methods to transgenic
mice with overexpression of vascular endothelial growth
factors VEGF-A or -C. Near-infrared dye conjugates were
developed to identify a suitable vascular tracer that had a
prolonged circulation lifetime and slow leakage into normal
tissue after intravenous injection. Dynamic simultaneous
imaging of ear skin and a large blood vessel in the leg enabled
determination of the intravascular signal (blood volume
fraction) from the tissue signal shortly after injection and
quantifications of vascular leakage into the extravascular tis-
sue over time. This method allowed for the sensitive detection
of increased blood vascularity and leakage rates in K14-
VEGF-A transgenic mice and also reliably measured
inflammation-induced changes of vascularity and leakage
over time in the same mice. Measurements after injection of
recombinant VEGF-A surprisingly revealed increased blood
vascular leakage and lymphatic clearance in K14-VEGF-C
transgenic mice which have an expanded cutaneous lymphatic
vessel network, potentially indicating unanticipated effects of
lymphatic drainage on vascular leakage. Increased vascular
leakage was also detected in subcutaneous tumors, confirming
that the method can also be applied to deeper tissues. This new
imaging method might facilitate longitudinal investigations of
the in vivo effects of drug candidates, including angiogenesis
inhibitors, in preclinical disease models.
Keywords Vascular permeability  Inflammation 
Imaging  VEGF-A  VEGF-C
Introduction
Leakage from the bloodstream to the interstitial tissue is a
tightly regulated process under normal physiological condi-
tions. The endothelial barrier, comprised of endothelial cells
and associated structures such as the glycocalyx, pericytes,
and basement membrane components, controls the rate of
leakage of water and plasma proteins to maintain tissue
homeostasis and to provide nutrients to cells [1]. In steady
state conditions there exists a slow filtration of fluid and
solutes from the capillaries to the tissue that is returned to the
circulation by the lymphatic system [2]. Under pathological
conditions such as inflammation, this balance is disrupted
leading to an influx of fluid and inflammatory cells that results
in tissue swelling or edema [3]. While most inflammatory
insults are acute in nature and resolve over time, chronic
inflammation such as the autoimmune disorders psoriasis and
rheumatoid arthritis can result in painful swelling and tissue
damage.
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A major factor leading to increased plasma leakage in
chronic inflammatory states is hyperpermeability of the
blood vessels, which is also a characteristic feature of other
disorders such as cancer and age-related macular degen-
eration [4]. A central mediator of vascular permeability is
vascular endothelial growth factor-A (VEGF-A). VEGF-A
exerts its effects acutely by vasodilation and by increasing
the gaps between endothelial cells and/or by inducing
formation of vesicular-vacuolar organelles in the cyto-
plasm [4, 5]. Chronic exposure to VEGF-A leads to an
expansion of the existing vessel network by increasing the
caliber of blood vessels and inducing the formation of new
blood vessels. The newly formed immature angiogenic
blood vessels further exacerbate chronic hyperpermeability
as they typically have incomplete pericyte and basement
membrane coverage.
Despite the importance of vascular hyperpermeability in
many pathological conditions, methods to accurately
measure vascular leakage in vivo in a non-invasive manner
are limited. Traditionally, the Miles assay has been used to
measure vascular leakage in skin and other organs [6]. This
assay involves an intravenous injection of Evans Blue dye
that binds to serum proteins (predominantly albumin) and
leaks from hyperpermeable vessels that are induced by
injections of acute permeability factors such as VEGF-A
into the skin [7]. Quantification of the leakage requires
sacrificing the animals and extracting the dye, a time-
consuming process that excludes longitudinal monitoring
or further analysis of the tissue. Furthermore, the assay in
its original form cannot distinguish between dye that is still
within blood vessels and that which has leaked [8], com-
plicating analyses in cases of increased vascular remodel-
ing. Attempts to address this issue, either with perfusion to
remove intravascular dye or with a two-tracer method that
involves injections at different time points to differentiate
the intravascular from the extravascular signals, have not
gained widespread acceptance due to their experimental
complexity [7, 9].
Recently, in vivo imaging approaches have been
developed that allow real-time visualization of vascular
leakage [10]. Dynamic contrast enhanced magnetic reso-
nance imaging, the most established of these techniques,
has advantages of increased imaging depth and good sen-
sitivity of contrast agents, but has a limitation of poor
resolution, allowing direct visualization of only the larger
blood vessels [11, 12]. In addition, the complex models
required for estimation of vascular permeability and the
expense of equipment limit its use to dedicated imaging
laboratories [9]. More recently, in vivo microscopy with
fluorescent tracers, such as FITC-dextran or rhodamine-
albumin conjugates, have been used to visualize vascular
leakage with high resolution in a dynamic manner [13, 14].
However, these methods typically involve special
experimental preparations such as dorsal skin-fold cham-
bers or exteriorization of tissue for visualization of a lim-
ited region of interest.
We hypothesized that a dynamic fluorescence approach
based on near-infrared (NIR) wavelengths could be used to
visualize vascular leakage in real time in intact mouse
tissues. NIR fluorescence imaging has gained popularity
due to its non-invasive nature and low cost instrumentation
[15]. The use of NIR wavelengths (650–900 nm) greatly
enhances tissue penetration and detection of signals due to
decreased tissue absorption and autofluorescence when
compared to the visible region of the electromagnetic
spectrum. Indocyanine green (ICG) is the only currently
clinically approved NIR dye. However, its short half life in
circulation may make it difficult to use in studies of vas-
cular leakage [16]. Tracers that show more stable fluores-
cent signals in the blood would improve the visualization
of leakage and allow quantifications to be developed. Such
methods could be applied to an array of mouse models and
allow long-term monitoring to test novel drug candidates.
In this study, we have developed NIR tracers and a
simple, reliable and rapid imaging protocol for visualizing
and quantifying vascular leakage in mouse tissues. We
used this method to measure vascular perfusion and leak-
age in transgenic mice with overexpression of VEGF-A
and -C in the skin and after local or systemic injections of
VEGF-A or -C. Additionally, measurement of leakage was
possible over the entire time course of chronic psoriasis-
like skin inflammation and in mice bearing 4T1 tumors.
Materials and methods
Transgenic mouse models
The generation of K14-VEGF-A transgenic mice that
express mouse VEGF-A164 under control of the K14
promoter and of K14-VEGF-C transgenic mice that express
full-length human VEGF-C have been described previously
[17–19]. K14-VEGF-A and K14-VEGF-C mice were bred
and housed in the animal facility of ETH Zurich. FVB
wildtype mice were used as controls. All experiments were
initiated when the mice were between 8 and 10 weeks of
age. Mice were fed alfalfa-free chow (Provimi Klibi AG,
Kaiseraugst, Switzerland) for at least 5 days prior to
imaging to reduce autofluorescence signals. Experiments
were performed in accordance with animal protocols
approved by the Veterinäramt Kanton Zurich.
Synthesis of PEG-IRDye
Methoxypoly(ethylene glycol) (PEG) amine P20 or P40
(20 or 40 kDa, respectively, 75 nmol) was dissolved in
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anhydrous DMSO. The monofunctional activated polymer
was labelled at room temperature for 6 h with 75 nmol
IRDye 800CW NHS Ester or IRDye 680LT NHS Ester
(D800 or D680, respectively, from LI-COR Biosciences,
Lincoln, NE) predissolved in DMSO. The crude reaction
was diluted in double-distilled water and lyophilized
overnight. The freeze-dried mixture was reconstituted with
250 lL of HEPES buffered saline (HBS, HEPES 20 mmol/
L, NaCl 142 mmol/L, pH 7.4) and purified using Fluores-
cent Dye Removal columns (Thermo Fisher Scientific,
Rockford, IL). The purity of the recovered compound (P20-
D680, P20-D800, P40-D680 or P40-D800) was controlled
by high-performance liquid chromatography, optimizing a
protocol previously described [20] as detailed in the
Electronic supplementary material. The efficiency of the
coupling procedure was assessed spectrophotometrically in
methanol on a Cary 300 Bio UV-spectrophotometer (Agi-
lent Technologies, Santa Clara, CA).
Pharmacokinetics (PK) study
Following tail vein injection of 0.05 nmol/g mouse weight
(expressed in terms of D800 content) of P20-D800 or P40-
D800 into wildtype 8 week-old mice (n = 3), serial blood
sampling from the saphenous vein (*30 lL) was per-
formed at t = 2 min, 15 min, 1 h and 3 h for P20-D800
and t = 2 min, 15 min, 1 h, 3 h and 6 h for P40-D800. A
final blood sample was collected under terminal anaesthe-
sia by cardiac puncture 6 h and 12 h post-injection for P20-
D800 and P40-D800, respectively. Urine was also collected
at the final time point. Blood samples were left to stand for
30 min and then were centrifuged at 3,0009g for 10 min.
Serum was collected and frozen at -20 C before analysis.
PK parameters were determined with a serum concentra-
tion time profile. Serum was deproteinized following a
protocol previously optimized [21], as detailed in the
Electronic supplementary material. To investigate the
presence of unbound dye at the end of the kinetics, samples
(t = 6 h) from animals injected with P20-D800 or P40-
D800 were analysed also via high-performance liquid
chromatography (HPLC). First serum was deproteinized,
and afterwards eluted in an analytical HPLC. P20-D800
and pure D800 dye were also eluted as controls.
Dynamic NIR imaging of vascular leakage
Mice were anesthetized with 2 % isoflurane and hair was
carefully removed in the region of the saphenous vein
using a razor and depilation cream at least 4 days prior to
imaging. During imaging, 2 % isoflurane was used for
anesthesia and the mice were positioned in an IVIS Spec-
trum imaging system (Caliper Life Sciences, Hopkington,
MA). A custom imaging platform and surgical tape were
employed to ensure reproducible positioning with the tis-
sues of interest and the saphenous vein region in the same
imaging plane. A sequence of 3 s exposure images (kex:
745 nm, kem: 800 nm, binning of 4) was initiated and
paused after the first image was acquired. Using a 30 g
insulin syringe, 0.05 nmol/g mouse weight (expressed in
terms of dye content) of PEG-IRDye solution was injected
intravenously into the tail vein and the sequence was
immediately resumed. Images were acquired every 15 s for
a total imaging time of 15–30 min depending on the
experiment. For experiments with 0.15 nmol/g mouse
weight of ICG dye solution, the images were acquired with
binning of 8 and exposure time of 5 s. Using Living
Image 4.0 software (Caliper), regions of interest over the
tissues of interest and the saphenous vein were drawn and
signal intensity values at each time point in fluorescent
counts were determined. The data were exported for
analysis as described in the Electronic supplementary
material.
Acute permeability studies
Human VEGF-A165, VEGF-C, and VEGF-C156S were
purchased from R&D Systems (Minneapolis, MN). For
examination of the effects of these proteins on vascular
leakage, a modified Miles Assay was developed and per-
formed in wildtype mice and in K14-VEGF-C (females,
10 weeks age, n = 5 each) mice. Briefly, mice were
injected with a 30 g syringe intradermally in one ear with
3 lL solutions of 30 ng of VEGF-A or VEGF-C and the
contralateral ear with PBS as a control. The mice were
immediately positioned in the IVIS and the imaging
sequence as above was initiated. Tail vein injections of the
imaging conjugates were performed on average 3 min after
the ear injections. Additionally, mice were examined for
vascular leakage in the ears after a tail vein injection of
1 lg of recombinant VEGF-A protein in solution along
with the dye conjugates. As systemic injection of VEGF-A
caused a detectable increase in blood vessel signal at early
time points, consistent with a vascular dilation effect, the
vascular leakage was monitored at the time point starting at
which the fluorescence enhancement reached a maximum,
which was typically around 2–3 min after injection.
Miles permeability assay
A solution of 0.2 mL of 0.5 % Evan’s blue dye (Sigma)
was administered by tail vein injection in wildtype mice
(n = 5). Immediately after this injection, a 3 lL solution
of 30 ng of VEGF-A was injected into the right ear while
the left ear was injected with PBS as a control. After
30 min, the ears of the mice were photographed and then
harvested from the sacrificed animals. The ears were split
Angiogenesis (2013) 16:525–540 527
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using forceps and placed in 0.5 mL of formamide at 55 C
for 24 h. The absorbance of the eluted dye was then ana-
lyzed by a plate reader (Tecan, Grödig, Austria) at 620 nm
along with standards for calculation of dye concentration.
Mouse model of chronic skin inflammation
For oxazolone-induced psoriasis-like skin inflammation in
the ear skin [22], K14-VEGF-A?/- transgenic mice
(n = 5, females, 10 weeks age) were anesthetized by i.p.
injection of 0.2 mg/kg medetomidine and 80 mg/kg keta-
mine, and 2 % oxazolone (4-ethoxymethylene-2 phenyl-2-
oxazoline-5-one; Sigma-Aldrich) in acetone/olive oil (4:1
v/v) was applied topically to the shaved abdomen (50 lL)
and to each paw (5 lL). Five days after sensitization (day
0), the right ear was challenged by topical application of
10 lL oxazolone (1 %) and the left ear remained untreated
as a control. Mice were imaged with the IVIS before sen-
sitization and at days 2, 9, 16, 23, and 30 after challenge.
Ear thickness was measured on the same days as imaging
using calipers. One mouse had obvious signs of inflam-
mation in the control ear (increased swelling and redness)
and therefore was excluded from the analyses.
4T1 model of breast cancer
4T1 mammary carcinoma cells (ATCC) were maintained
in DMEM-Glutamax (Invitrogen), supplemented with
10 % FCS (Invitrogen). Cells were retrovirally transduced
with MSCV-IRES-Venus (kind gift from Dr. Johannes
Zuber, IMP, Vienna, Austria). Retroviral supernatants were
produced by transiently transfecting the HEK-293T pack-
aging cell line by standard calcium phosphate transfection
techniques. Harvested supernatants were filtered through a
0.45-lm filter and stored at -80 C. 4T1 cells were cul-
tured in the presence of retrovirus-containing supernatants
and polybrene (4 lg/mL) for 12 h each for a total of 6
transfection cycles. Following the last incubation, cells
were cultured for at least 72 h. FACS sorting was
employed to obtain a stable population of 4T1-MSCV
Venus cells with a high level of fluorescence. 4T1-MSCV-
Venus cells (5 9 104) were injected subcutaneously into
the rear right flank of 8-week old female Balb/c mice
(Janvier, Le Genest Saint Isle, France). Mice were imaged
at 14 days (with IVIS) after tumor inoculation at which
time tumors were approximately 8–10 mm in diameter.
Statistics
Statistical analysis was performed using Prism version 4.03
(GraphPad Software, Inc.). Data are shown as mean ± SD
and were analyzed with a two-tailed unpaired Student’s
t test. When more than two groups were compared,
ANOVA was applied and the individual groups were
compared using a Tukey-HSD post hoc test.
Results
Development of NIR vascular leakage tracers
We first designed NIR dye-conjugates to identify a vas-
cular tracer for imaging with the desired features of stable
vascular signals at early time points after injection and a
suitable clearance profile. The molecular weights of the
polymeric backbone of the tracers (20 or 40 kDa, Table 1)
were chosen in order to avoid a prolonged circulation
lifetime that would have hampered longitudinal studies.
The tracers (P20-D800 or P40-D800) were prepared by
coupling the PEG to the NIR dye IRDye 800CW (D800).
We next evaluated the PK profiles in serum and bio-
distribution of the two conjugates (Table 1, Supplementary
Figs. 1 and 2). We sampled blood at select time points after
injection of the tracers (Supplementary Fig. 2) and deter-
mined terminal serum half-lives of 2 h 25 min for P20-
D800 and 12 h 35 min for P40-D800 (Table 1). The rela-
tively slow elimination, as expected for a macromolecule,
resulted in almost constant tracer concentration in blood for
the first 15 min after the injection. The apparent volume of
distribution (Vd) of both tracers was found to be similar to
the total serum volume of mice, indicating that the NIR
dye-conjugates remained initially in the bloodstream and
did not distribute rapidly to the tissues. Both tracers were
excreted in intact form through renal filtration (Supple-
mentary Fig. 2). Lower signals were seen in all evaluated
tissues in the P20-D800 injected versus the P40-D800
animals at one week post injection, confirming the much
slower clearance of the latter (Supplementary Fig. 2d).
Table 1 Pharmacokinetic parameters of P20-D800 and P40-D800 after intravenous administration
Sample Calculated RH (nm) Mn/NMR (kDa) Kel (h
-1) t1/2 (h) AUC0–? (lmol 9 h/mL) CL (mL/h) Vd (mL)
P20-D800 4.2 21.5 0.30 ± 0.06 2.43 ± 0.73 2.71 ± 0.34 0.54 ± 0.10 1.81 ± 0.15
P40-D800 5.8 37.9 0.058 ± 0.019 12.6 ± 4.3 14.4 ± 3.0 0.09 ± 0.02 1.62 ± 0.21
Administered dose (expressed as D800 content): 0.05 nmol/g body weight. Data are expressed as mean ± SD (n = 3)
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We then collected a dynamic series of NIR images after
intravenous administration in normal mice that allowed
real-time assessment of signal intensities of the fluorescent
tracers compared to the established tracer ICG. ICG
showed immediate saphenous vein vessel enhancement
followed by rapid decreases in blood vessel intensity, while
P20-D800 and P40-D800 dye conjugates reached a quasi-
equilibrium in the bloodstream rapidly with almost no
change in signal during the duration of imaging (Fig. 1a).
In ear tissue, ICG signal rapidly decreased after an initial
enhancement, while P20-D800 showed a slowly increasing
signal indicating that the conjugate leaked out of normal
skin blood vessels but at a very low rate (Fig. 1b). P40-
D800 showed stable signal similar to that seen at the
saphenous vein, suggesting that this tracer remains pre-
dominantly intravascular during the period of imaging.
P20-D800 cleared faster from the ear tissue than P40-
D800 (Fig. 1c, d), allowing longitudinal imaging with low
background at earlier time points. At 72 h after injection,
mice injected with P20-D800 had approximately 20 % of
the signal intensity in the ear that was seen at 3 h, while
P40-D800 injected animals retained around 80 % of the
signal. Based on the stability of fluorescence signals at
early time points and the clearance profile, we mainly
focused our subsequent experiments on P20-D800.
Quantification of tissue vascularity and leakage
We assumed a two-compartment model for tissue to develop
quantifications of vascular leakage, in which the first com-
partment was defined as the intravascular compartment
(blood) of the tissue and the second was defined as the
extravascular compartment (comprised of interstitium and
lymphatic vessels) (Fig. 2a). Based on the revised Starlings
forces and the size of the fluorescent tracers, we assumed
that there was one-way movement of the tracers from the
intravascular to the extravascular compartment and that
return of the tracers to the blood via the venous system was
negligible [2]. We also assumed that clearance out of the
tissue of the leaked tracers by the lymphatic vessels would
be negligible in the initial timepoints. By performing
simultaneous dynamic imaging on both the saphenous vein
region (assumed as 100 % intravascular) and the ears
(Fig. 2b), we were then able to derive quantifications based
on normalization of the tissue fluorescence signal to the
blood vascular signal. This allowed for an estimation of the
blood volume fraction of the tissue shortly after the injec-
tion, and with dynamic imaging, an assessment of the
increase in extravascular signal over time.
The quantifications were initially developed in normal
mice after tail vein injection of P20-D800. By plotting of
Fig. 1 Development of a
suitable vascular leakage tracer.
a Comparison of the dynamics
after tail vein injection of ICG
(n = 10), P20-D800 (n = 10),
or P40-D800 (n = 6) into
normal mice. Normalized
saphenous vein signals plotted
over time after i.v. injection.
b Normalized ear signals after
i.v. injection. c Representative
images of the ears after i.v.
injection to show the clearance
of signal over time between
P20-D800 and P40-D800.
d Quantification of the
clearance of signal
(mean ± SD) in the ears for
n = 3 mice between P20-D800
and P40-D800. Data is
normalized to the ear signal
intensity at 3 h. * p \ 0.05,
** p \ 0.01, *** p \ 0.001
Angiogenesis (2013) 16:525–540 529
123
fluorescent signal intensities over time from regions of
interest drawn on the ears and saphenous vein (Supple-
mentary Fig. 3), we found that there were no effective
changes in signal from the time quasi-equilibrium was
reached in the bloodstream at t = 1 min until t = 20 min
(Fig. 2c). However, when the ear signal enhancement
(ESE) values were normalized to the saphenous vein signal
enhancement (SVSE) values, there were positive slopes
over time indicating slow leakage of P20-D800 into tissue
(Fig. 2d). From this plot we derived two quantifications
based on the assumptions of the two-compartment model.
The first, calculated at the time point that blood signal
equilibrium was reached after the i.v. injection, was termed
blood volume fraction (BVF) and represents an estimate of
the intravascular compartment (perfused blood vessels) in
the tissue relative to the region of assumed 100 % vascu-
larity, the saphenous vein. Normal mouse ears typically
displayed blood volume fraction values of approximately
0.1 (i.e. 10 % vascularity). The second value was defined
as the slope of the ESE/SVSE values over time and was
termed tissue leakage rate (TLR, expressed in min-1). This
value represents the increase in signal in the extravascular
Fig. 2 Quantifications of blood
volume fraction, tissue leakage
rate and vascular leakage rate in
normal mice. a Two-
compartment model for
development of quantifications
of vascular leakage using NIR
tracers. b Sequence of images
demonstrating the animal
positioning and dynamics of
P20-D800 signal in the
saphenous vein and ears in a
normal mouse for measurement
of vascular leakage. c Signal
intensity plots for regions of
interest over the saphenous vein
and ear exhibit stable
fluorescence intensities after
injection. d Plot demonstrating
measurements of tissue leakage
rate (slope of linear fit equation)
and blood volume fraction
(indicated by arrow). Units are
presented as ratio of ear signal
enhancement (ESE) to
saphenous vein signal
enhancement (SVSE).
e Normalized plot showing
measurement of vascular
leakage rate (slope of linear fit
equation). Units are presented as
ratio of normalized ear signal
enhancement (NESE) to
normalized saphenous vein
signal enhancement (NSVSE)
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compartment over time. Normal mouse ears exhibited a
very low TLR of P20-D800 tracer (*0.1 % of the ESE/
SVSE per min). Since tissue leakage rates are dependent on
the surface area of the blood vessels available for filtration,
it was necessary to adjust TLR by normalization to BVF
(Fig. 2e), to calculate the vascular leakage rate (VLR,
expressed in min-1). It is important to note that the cal-
culated leakage rates will be dependent on not only vas-
cular permeability but also on the rates of interstitial fluid
flux and lymphatic uptake.
We next compared the BVF, TLR, and VLR values in
normal mice that were injected with either P20-D800 or
P40-D800 (Supplementary Fig. 4a). We found that mice
injected with the smaller tracer P20-D800 had significantly
higher TLR (p \ 0.001) and VLR (p \ 0.01) values com-
pared to mice injected with P40-D800, with no significant
difference in BVF. Using a stereomicroscope adapted for
far-red wavelengths for higher resolution dynamic visual-
ization of the leakage in the ear, we validated that P20 dye
conjugates are leaking into normal skin tissue, while P40
dye conjugates appear to stay intravascular during the
30 min after injection (Supplementary Fig. 4, Supplemen-
tary Movies 1 and 2). Thus, these findings reveal that P20-
D800 showed steady-state leakage out of blood vessels into
normal skin tissue.
Quantification of vascularity and leakage in transgenic
mice with overexpression of VEGF-A or VEGF-C
in the skin
We next compared wildtype mice with transgenic mice that
express murine VEGF-A164 specifically in the skin under
control of the keratin-14 promoter. K14-VEGF-A homo-
zygous mice (K14-VEGF-A?/?) have increased blood
vascular density in the skin with enhanced vascular leakage
as shown with the Miles assay and development of skin
inflammation resembling psoriasis [18, 19]. K14-VEGF-A
hemizygous mice (K14-VEGF-A?/-) have less expression
of VEGF-A and show increased skin vascularity over
normal mice but no spontaneous development of inflam-
mation [22, 23]. We also analyzed K14-VEGF-C trans-
genic mice that have been reported to have an expanded
lymphatic vessel network with no changes in blood vas-
cular density [17].
After injection of P20-D800, the increased vascularity in
the K14-VEGF-A?/? mice was clearly seen compared to
the wildtype at the 1 min time point. A slight increase in
vascularity could be visualized in the K14-VEGF-A?/-
mice. The increased tracer leakage in the K14-VEGF-A?/?
mice over the other genotype mice was apparent by the
increased blurring and brightness seen at later time
points (Fig. 3a). TLR graphs (Fig. 3b) show increases in
slopes in the K14-VEGF-A?/- and K14-VEGF-A?/? mice
compared to wildtype (Fig. 2c) and K14-VEGF-C mice,
reflecting the increased leakage of P20-D800 in these mice.
With quantifications (Fig. 3c), K14-VEGFA?/- mice
demonstrated a 1.8-fold increase in BVF over wildtype
controls (p \ 0.01), whereas K14-VEGF-A?/? mice had a
more variable 6.5-fold increase (p \ 0.001). K14-VEGF-C
mice showed no difference in BVF compared to wildtype.
TLR was sixfold increased in K14-VEGF-A?/- mice
compared to wildtype mice (p \ 0.001). In K14-VEGF-
A?/? mice, TLR values were significantly higher than both
wildtype (31-fold, p \ 0.001) or K14-VEGF-A?/- mice
(5.2-fold, p \ 0.001). The high variability seems to be
inherent in the K14-VEGF-A?/? model, as examination of
the ears of the mice showed obvious inflammation with
different degrees of vascularity and redness, even between
ears of the same animal (Supplementary Fig. 5).
After normalization for the differences in BVF, we
found a highly significant 3.3-fold increase of VLR
(p \ 0.001) in K14-VEGF-A?/- versus wildtype mice
(Fig. 3c). K14-VEGF-A?/? mice also displayed significant
increases in VLR over wildtype (4.7-fold, p \ 0.001) and
K14-VEGF-A?/- (1.5-fold, p \ 0.05) mice. In K14-
VEGF-C transgenic mice, we found no significant differ-
ences in TLR and VLR compared to wildtype controls.
These results confirmed that the developed imaging
method is able to adequately detect changes in vascularity
and leakage in different genetic mouse models.
Reliable quantification of the changes in vascularity
and leakage during the course of chronic inflammation
We next measured the inflammation-associated blood
vascular changes over time in K14-VEGF-A?/- mice in
response to a contact hypersensitivity reaction induced
with oxazolone [24]. In this model of psoriasis-like
inflammation, a strong increase in ear swelling is seen
within hours after antigen challenge. Peak swelling is
reached around Day 2 after challenge and slowly dimin-
ishes over time, allowing serial imaging of the vascular
response (Fig. 4a). We challenged the right ear with oxa-
zolone and the left ear remained untreated as a control.
Imaging was performed before challenge and every 7 days
starting at Day 2.
A dramatic increase in tissue leakage in the oxazolone-
challenged right ear was seen 20 min after intravenous
injection of P20-D800 at Day 2 of inflammation (Fig. 4b).
Repeated imaging of the same mouse showed diminishing
leakage on Days 16 and 30 after challenge. In contrast, the
unchallenged left ear showed no obvious differences in
leakage at the different time points (Fig. 4b). Quantifica-
tions (Fig. 4c) demonstrated highly significant increases in
the challenged ear compared to the unchallenged ear in
BVF (2.4-fold, p \ 0.001) at Day 2. BVF peaked at Day 9
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(2.8-fold, p \ 0.01) and then declined slowly over time
with no significant difference (p = 0.07) to unchallenged
ears at Day 30 after challenge. We found that TLR peaked
at Day 2 in challenged ears (5.2-fold over control,
p \ 0.001) and then decreased steadily over time. At Day
30, TLR was still significantly higher than in unchallenged
ears (1.8-fold, p \ 0.05). VLR was significantly higher at
Day 2 (2.3-fold over control, p \ 0.001) and then showed
no significant difference compared to control values as
early as Day 9 after challenge. Ear thickness showed a
closer correlation with TLR than with BVF or VLR over
time (Supplementary Fig. 6). These results indicate that the
in vivo imaging with P20-D800 can reproducibly track
vascularity and leakage changes in longitudinal studies of
chronic inflammation.
K14-VEGF-C mice demonstrate increased leakage
rates after VEGF-A injection
We next investigated whether the developed imaging
method was sensitive enough to quantify changes in vas-
cular leakage in response to injections of VEGF-A. Vas-
cular leakage has been reported to be acutely induced
within a few minutes of injection of VEGF-A due to
Fig. 3 Vascularity and leakage in transgenic mice with overexpres-
sion of VEGF-A and VEGF-C in the skin. a Representative images of
ears from wildtype, K14-VEGF-A?/-, K14-VEGF-A?/? and K14-
VEGF-C?/- transgenic mice at pre-injection, 1, 10, and 20 min after
injection of P20-D800 tracer. b Sample plots of tissue leakage rates
from K14-VEGF-A?/- (left), K14-VEGF-A?/? (middle), and K14-
VEGF-C?/- (right). c Distribution plots showing quantifications of
BVF, TLR, and VLR for groups (n = 5) of transgenic mice.
* p \ 0.05, ** p \ 0.01, *** p \ 0.001
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vasodilation and increases in blood vessel permeability [7].
This is followed by rapid internalization and deactivation
of the growth factor by its receptor VEGFR2 and attenu-
ation of the leakage effect [7, 25].
We first analyzed vascular leakage after intradermal
injections of 30 ng human VEGF-A165 or saline control into
wildtype and K14-VEGF-C mouse ears (Fig. 5a). A tradi-
tional Miles assay in wildtype mice with this protocol
resulted in a significant 3.2-fold increase (p = 0.05) in
Evans Blue dye concentration in the VEGF-A injected ear
over the control ear at 30 min after injection (Supplementary
Fig. 7). For imaging of this response, we initiated our
imaging sequence with tail vein injections of P20-D800
tracers approximately 3 min after the ear injections. In
wildtype mice, a minor increase (1.3-fold, p = 0.16) was
found in BVF in the VEGF-A injected ears over the saline
injected ears. In K14-VEGF-C mice, the increase in BVF
was significant (1.7-fold, p \ 0.01). Significant increases
were found in both TLR (4.7-fold, p \ 0.05) and VLR (3.4-
fold, p \ 0.001) in the VEGF-A injected ears in wildtype
animals. In K14-VEGF-C mice, we also found significant
increases in both TLR (8.2-fold, p \ 0.001) and VLR
Fig. 4 Validation of
reproducibility and longitudinal
imaging in chronic skin
inflammation model. a Timeline
of induction and imaging points
of the contact hypersensitivity
model in K14-VEGF-A?/-
mice. b Sample images of one
mouse taken at 20 min after
injection of P20-D800 tracer at
Day 2 (left), Day 16 (middle),
and Day 30 (right). Right ear
was challenged with oxazolone
while the left remained
unchallenged. c Quantifications
(mean ± SD) over time in same
cohort of mice (n = 5) for BVF
(upper left), TLR (upper right),
VLR (bottom left), and ear
thickness (bottom right).
* p \ 0.05, ** p \ 0.01,
*** p \ 0.001 versus control
ears
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(3.6-fold, p \ 0.001) in VEGF-A injected ears. K14-VEGF-
C mice exhibited significantly increased TLR values (2.2-
fold, p \ 0.001) over wildtype animals in response to
VEGF-A, indicating that leakage is enhanced in these ani-
mals. We found that in K14-VEGF-C mice, the leakage was
occurring so rapidly in response to VEGF-A that it was
impossible to quantify accurately the BVF values, as leakage
had begun prior to the time point when equilibrium was
reached in the bloodstream. Despite these increased BVF
values, which may also reflect to some extent vascular
dilation, we were able to detect a significant higher VLR
(1.7-fold, p \ 0.001) in K14-VEGF-C animals over wild-
type after VEGF-A injection.
Since intradermal injections may cause vascular damage
and significant leakage occurred even in saline injected
tissue, we next performed imaging after tail vein injection
of 1 lg human VEGF-A165 in conjunction with P20-D800
dye. As seen in Fig. 5b, the saphenous vein signal in both
wildtype and K14-VEGF-C mice showed vascular dilation
in the initial 2 to 3 min, followed by a steady decrease in
fluorescence, likely due to systemic leakage effects. During
the time directly after maximum enhancement was
Fig. 5 Acute permeability measurements after injections of human
VEGF-A165. a Quantifications (mean ± SD) demonstrating differ-
ences between wildtype and K14-VEGF-C?/- (n = 5) mice after
injections of 30 ng VEGF-A or PBS into the ear skin. b Sample signal
intensity plots after tail vein injections of 1 lg VEGF-A and P20-
D800 tracer in wildtype (left) and K14-VEGF-C?/- (right). c Quan-
tifications demonstrating differences in BVF (left), TLR (middle), and
VLR (right) between wildtype and K14-VEGF-C?/- mice after
tail vein injections of 1 lg VEGF-A. * p \ 0.05, ** p \ 0.01,
*** p \ 0.001
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reached, leakage rates in the ear skin were quantified in
wildtype and K14-VEGF-C mice (Fig. 5c). After intrave-
nous administration of VEGF-A, leakage occurred at a
slower rate than after skin injection and BVF values could
therefore be calculated with more accuracy. With this
protocol, we found no significant difference in BVF
(p = 0.34) between wildtype and K14-VEGF-C mice.
However, we again found significant increases in TLR
(2.7-fold, p \ 0.001) and VLR (2.5-fold, p \ 0.001) in
K14-VEGF-C over wildtype mice. Using high-resolution
dynamic stereomicroscopy we confirmed these results.
After ears of wildtype and K14-VEGF-C mice were posi-
tioned under the microscope, the mice were injected with
1 lg of VEGF-A and P20-D680 into the tail vein. As
shown in Supplementary Movies 3 and 4, the K14-VEGF-
C mouse ear has increased spreading of signal around the
blood vessels over time, indicating faster leakage compared
to the wildtype mouse.
Expanded dermal lymphatic network and rapid
lymphatic clearance after acute permeability reaction
in K14-VEGF-C mice
The unexpected finding of increased vascular leakage rates
during an acute permeability reaction seen in the K14-
VEGF-C mice led us to investigate these mice further. To
visualize the lymphatic network of the ear, we performed
fluorescence lymphangiography with a stereomicroscope
after an injection of P40-D680 tracer into the tip of the ear
(Fig. 6a). Immediately after the injection, the tracer filled
an expanded dermal network of lymphatic vessels with no
uptake into blood vessels. The lymphatic network appeared
to fill most of the available space with the exception of the
hair follicles, as described previously [26]. The tracer
exhibited rapid lateral spreading throughout this dermal
network and eventual absorption into the collecting vessels
of the ear. By comparison, the wildtype mice demonstrated
Fig. 6 Visualization of the
lymphatic vasculature in the
ears and clearance of tracer after
acute leakage.
a Lymphangiography after
intradermal injection of P40-
D680 into the ears of wildtype
(left) and K14-VEGF-C (right)
mice. Inset in right panel shows
higher magnification of
expanded lymphatic capillaries
in the K14-VEGF-C?/- ear. b
Representative lymphatic
clearance of P20-D800
(normalized to ear signal
enhancement at 40 min after i.v.
injection) from VEGF-A
injected ears in wildtype (left)
and K14-VEGF-C?/- (right)
mice. R2 values show close fit to
a model of one-phase
exponential decay.
c Quantifications of half-life and
K rate values decay curves as
measures of lymphatic
clearance in wildtype (n = 5)
and K14-VEGF-C?/- (n = 4)
mice. * p \ 0.05, ** p \ 0.01,
*** p \ 0.001
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a less dense network of lymphatic capillaries with no lat-
eral spreading of the tracer.
The expanded network of lymphatic vessels in K14-
VEGF-C mice has been suggested to be dysfunctional and
associated with retrogradal flow [17, 26]. However, we
recently observed increased lymphatic clearance in these
mice over wildtype controls at 16 h after intradermal Evans
Blue dye injection [27]. To further investigate this issue,
we developed a protocol in which the decay of signal in the
ear is monitored after tracer leakage from blood vessels is
induced by an acute permeability reaction to VEGF-A. The
permeability effect is short-lived after injection of VEGF-
A (Supplementary Fig. 8) and therefore vascular leakage of
the tracer at later time points is considered to be negligible
[4, 25]. Therefore, this approach may quantify lymphatic
clearance in a more relevant setting compared to clearance
directly after tracer injections into ear skin, which likely
cause supraphysiological interstitial pressures and over-
loading of lymphatic vessels [28, 29]. As shown in Fig. 6b,
a representative K14-VEGF-C mouse had enhanced tissue
clearance of the tracer signal compared to wildtype. These
data very closely fit (R2 [ 0.99) to a one-phase exponential
decay model in which the clearance of signal can be
expressed by rate constant K or by half-life quantifications
(Fig. 6c). The average half-life of clearance in K14-VEGF-
C mice was significantly shorter (p \ 0.001) than in wild-
type mice with K rates significantly higher (p \ 0.001),
indicating that the lymphatic clearance of the extravasated
tracer is accelerated in these mice.
The mature form of VEGF-C induces vascular leakage
via VEGFR2
We next investigated whether human VEGF-C can have acute
effects on vascular leakage by injecting both non-mutated and
mutated forms of fully processed VEGF-C into the ear and tail
veins of wildtype mice. The non-mutated fully processed
form of VEGF-C has been shown to activate VEGFR-3 and
VEGFR-2 while the mutant form VEGF-C156S is only able
to activate VEGFR-3 [30]. We first tested these proteins at the
same dose (30 ng of protein injected into the ear skin) that
was used to induce leakage with VEGF-A. As shown in
Fig. 7, we found increased TLR and VLR values with this
dose of VEGF-A but no significant changes were seen at this
dose with either form of VEGF-C. Similarly, no increases in
leakage rates over normal wildtype mouse values were found
after tail vein injection of 1 lg of VEGF-C (TLR:
0.0013 ± 0.0004 vs. 0.0011 ± 0.0005 min-1, n = 3). We
hypothesized that reduced affinity of VEGFR-2 for mature
VEGF-C compared to VEGF-A may be an explanation for the
lack of effects [31]. After ear injections of a higher dose of
300 ng of VEGF-C, we saw significant increases over PBS
injected ears in TLR (2.5-fold, p \ 0.001) and VLR (twofold,
p \ 0.01) when the native form of VEGF-C was injected, but
no significant differences in these parameters with the mutant
form (Figs. 7b, c). These findings indicate that fully processed
VEGF-C can exert leakage effects on blood vessels via acti-
vation of VEGFR-2.
Quantification of vascular leakage in subcutaneous
4T1 tumors
We next determined if the vascular leakage methods could
be adapted for evaluation of deeper tissues, specifically in
tumor models where preclinical assessment of the response
to anti-angiogenic therapy is critical in the drug develop-
ment process. We first compared the signal detection of
P20-D800 versus ICG and a commonly employed vascular
tracer in the visible wavelength spectrum, BSA-Rhodamine
[14] through a 1-cm thick chicken breast tissue phantom.
As seen in Supplementary Fig. 9, 21 % of signal from P20-
D800 was detected through the phantom, compared to
18 % of ICG and less than 2 % of BSA-Rhodamine.
Next, we tested the tracers in mice bearing subcutaneous
4T1 tumors by performing vascularity and leakage mea-
surements in the tumor versus a normal tissue region of the
Fig. 7 Acute permeability measurements after ear injections of native and mutant forms of fully processed human VEGF-C (n = 6).
a Quantifications (mean ± SD) of BVF. b TLR. c VLR. * p \ 0.05, ** p \ 0.01, *** p \ 0.001
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same mice after tail vein injection of P20-D800 (Fig. 8a).
As seen in Fig. 8b, BVF values were significantly higher
(1.3-fold, p \ 0.001) in the tumor compared to the normal
tissue. The vasculature in the tumor region exhibited higher
leakage as seen by significant increases in both TLR
(threefold, p \ 0.001) and VLR (2.8-fold, p \ 0.001)
compared to normal tissue (Figs. 8c, d). Higher-resolution
dynamic imaging of the tumor associated blood vessels,
using a stereomicroscope, also demonstrated significant
leakiness after intravenous injection of P20-D680 (Fig. 8e;
Supplementary Movie 5).
Discussion
Regulation of vascular permeability is a critical feature of
the microvasculature and alterations in plasma leakage
occur in a wide spectrum of conditions. Despite its
importance, techniques that can non-invasively quantify
vascular leakage in mouse models are quite limited.
Established preclinical methods for measuring vascular
leakage require either sacrifice or exteriorization of tissue
(e.g. Miles assay, FITC-conjugates), or technically
demanding and expensive techniques (e.g. MRI, window
chambers for in vivo confocal microscopy) [9, 10]. In this
study, we have established and validated imaging methods
and quantifications based on visualization of new NIR
tracers that can easily monitor vascular perfusion and
leakage within an intact animal, using a commonly avail-
able preclinical imaging device. The chosen tracers resul-
ted in an optimal balance between stability in the blood—
allowing short-term measurements of leakage—and a
clearance compatible with the needs for longitudinal
studies.
NIR imaging has great potential for non-invasive
imaging due to increased penetration into tissue at these
wavelengths. The decreased absorption by water and
hemoglobin at these wavelengths and reduced heating
effects over visible wavelengths are particularly critical for
measurements of vascular leakage. ICG is the most com-
monly used NIR dye due to its clinical approval and
characteristic binding to serum proteins including albumin
once injected into the bloodstream [16]. However, we
determined that the extremely short half-life of ICG
(*2 min) [32] led to high variability in the serum decay
rates between different animals. These features would
make it difficult to visualize the leakage of this dye except
in cases of extremely leaky vessels. Additionally, ICG has
other features that make it unsuitable for accurate and
sensitive quantification of vascular leakage, such as dye
oligomerization and subsequent self-quenching, and a lack
of reactive moieties that hinder its conjugation to other
molecules [33, 34]. While liposomal formulations of ICG
with improved in vivo stability have been demonstrated for
Fig. 8 Measurement of vascularity and leakage in a 4T1 subcutane-
ous tumor model (n = 6). a Positioning of 4T1 bearing mice for
measurement in IVIS and visualization of increased signal in the 4T1
tumor compared to normal tissue region at 1 min after intravenous
injection of P20-D800. b Quantification of BVF. c TLR. d VLR.
e Stereomicroscope imaging of 4T1 tumor blood vessels. The left
image shows blood vessels and Venus positive tumor fluorescence as
seen using a GFP filter set. The three additional panels show imaging
with a Cy5 filter set at different time points (30 s, 5 min, and 10 min)
after intravenous injection of P20-D680 tracers. Note increase in
signal outside blood vessels over time, indicating vascular leakage in
the tumor. * p \ 0.05, ** p \ 0.01, *** p \ 0.001
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both vascular and lymphatic imaging, the size of these
particles (60–200 nm) would severely diminish vascular
leakage rates, limiting the quantification potential [35, 36].
Therefore, we aimed to develop improved tracers based
on a newly developed dye, IRDye 800CW (D800). This
dye has several advantages over ICG including increased
brightness, ease of conjugation, and long-term stability
[34]. Additionally, it has begun a clinical approval process
with no adverse effects seen in preclinical studies [34].
However, D800 when injected in its carboxylated form
leaks extremely rapidly from blood vessels due to its small
size and lack of binding to serum proteins. Therefore, we
developed conjugates by binding the amine reactive form
of this dye (IRDye 800CW NHS ester) to the hydrophilic
polymer PEG, an FDA-approved macromolecule widely
used in drug delivery due to its safety profile, low immu-
nogenicity, and ability to prevent protein and cell absorp-
tion [37]. The size of these conjugates allowed prolonged
circulation lifetime with respect to the free dye and at the
same time an effective longitudinal screening due to the
good clearance [38]. In addition, we found that the 20 kDa
form demonstrated reproducible steady-state vascular
leakage into the skin that could be visualized noninvasively
in a matter of minutes.
Acquisition of a short dynamic series of NIR images
allowed quantification of vascular perfusion and leakage
rates in mouse skin with remarkable consistency, as seen
by our results analyzing transgenic mice as well as during
our longitudinal study. A key advance allowing such
reproducible measurements to be developed was normali-
zation of tissue signals to a vascular region of interest, the
saphenous vein, which provided adjustments for variations
in delivered tracer dose, tissue blood volume fractions, and
the dynamics of blood signal. Comparison to the current
gold standard, the Miles assay, highlighted the numerous
limitations of the existing method as indicated by previous
investigators [8]. Although both methods were able to
demonstrate significantly increased leakage in response to
VEGF-A injections into the skin, the Miles assay gave only
information on total tissue concentration of the dye at
30 min after injection and required sacrifice of the animal.
In situations of increased vascularity, such as in the VEGF-
A transgenic animals or under inflammatory conditions, the
Miles assay would be even more limited because it cannot
provide adjustments for increased vascular surface area.
Both methods, however, are not designed to distinguish
between intercellular and transcellular routes of vascular
leakage.
Although intradermal injections are the most widely
used route to test permeability factors, we found high
variability in our measurements, even in the saline control
group. It is likely that direct injections into the skin can
rupture blood vessels and/or cause increases in hydraulic
conductivity that can increase transport of tracers from
plasma through the interstitium. When the protein was
injected intravascularly along with the tracer, we were able
to quantify leakage effects much more consistently. By
limiting the technical variability in making measurements
of vascular leakage, we were able to determine highly
significant differences with even small numbers of mice.
Additionally, the ability to accurately image repeatedly in
the same cohorts of mice gives researchers a powerful tool
that can reduce the effects of inherent biological variability
by providing an intra-individual baseline measurement in
longitudinal studies of therapeutic interventions, poten-
tially reducing the number of animals needed for such
studies. As permeability changes occur quite rapidly in
response to drug interventions, sensitive in vivo readouts of
vascular leakage could represent a major step forward in
the preclinical phase of drug development.
The increases in vascular leakage in K14-VEGF-C
overexpressing mice after VEGF-A was administered may
highlight an important compensatory role of a functional
lymphatic system during conditions of hyperpermeability.
The K14-VEGF-C mice have an expanded network of
dermal lymphatics and enhanced lymphatic function, as
shown by increased clearance of the tracers after extrava-
sation or after skin injection of Evans Blue dye [27]. The
hyperplastic lymphatic capillaries in these animals were
previously suggested to be less functional [17, 26]. How-
ever, the increased surface area available for absorption
may accelerate lymphatic clearance and together with
increased vascular leakage rates, result in enhanced ‘‘tissue
flushing.’’ Recent data from our lab and others indicate a
key role for functional lymphatic vessels induced by
VEGF-C overexpression in limiting inflammation and
accelerating diabetic wound healing [27, 39–41]. An
expanded lymphatic network may be more primed to deal
with an inflammatory insult by limiting interstitial fluid
pressure and the resultant tissue swelling. This increased
‘‘edema safety factor’’ may partly explain the lack of
regression of newly formed lymphatic vessels after reso-
lution of chronic inflammation [42, 43].
Although the connection of VEGF-A and angiogenic
vessels to increased vascular permeability is well estab-
lished, the relationship between the functionality of the
lymphatic system and vascular leakage has not been
extensively studied. Dysfunctional lymphatic function has
been speculated as part of the reason for the enhanced
permeability and retention effect that aids delivery of
nanoparticles to tumors [44]. However, in contrast to this,
the high interstitial pressure that can result from chronic
hyperpermeability and poor lymphatic function has also
been considered as a barrier to drug delivery [45]. As the
lymphatic network represents the only exit route from the
interstitium for macromolecules, an improved or
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diminished function of this system likely will also have an
effect on the rate of capillary filtration as predicted by the
revised Starling equation [1, 3]. Thus, VEGF-C might
enhance vascular leakage by two different mechanisms—
direct effects of the processed form on blood vasculature
endothelium via activation of VEGFR2, as shown by pre-
vious studies [46, 47] and in our intradermal injection
experiments, and indirect effects via establishment of a
more efficient lymphatic drainage network. Although more
work is necessary to validate this hypothesis, our findings
may hint at strategies to improve lymphatic function to
supplement existing therapies and enhance the resolution
of chronic inflammatory disorders. Tools that can evaluate
blood volume fraction and vascular leakage rates such as
developed in the current study would allow for improved
monitoring of drug penetration and response in these
conditions.
We have successfully applied the noninvasive mea-
surements of blood volume fraction and vascular leakage to
a subcutaneous 4T1 tumor model. The increased depth
penetration of NIR tracers allows for measurement of tis-
sues at least 1 cm deep, as evidenced by tissue phantom
experiments and our previous experience of deep iliac
lymph node detection in mice with ICG liposomes [36].
When we performed measurements in the 4T1 tumor, we
were able to detect significantly increased vascularity and
leakage rates compared to normal tissue, thus enabling
future studies to evaluate the effects of anti-angiogenic
therapies on these parameters which might facilitate the
drug development process.
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